Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 (n = 16) or placebo (n = 15) in addition to standard of care. AMY-101 was safe and well tolerated. Compared to placebo (8 of 15, 53.3%), a higher, albeit nonsignificant, proportion of AMY-101–treated patients (13 of 16, 81.3%) were free of supplemental oxygen at day 14. Three nonresponders and two placebo-treated patients succumbed to disease-related complications. AMY-101 significantly reduced CRP and ferritin and restrained thrombin and NET generation. Complete and sustained C3 inhibition was observed in all responders. Residual C3 activity in the three nonresponders suggested the presence of a convertase-independent C3 activation pathway overriding the drug’s inhibitory activity. These findings support the design of larger trials exploring the potential of C3-based inhibition in COVID-19 or other complement-mediated diseases.

[1]  Jamie B. Spangler,et al.  IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function , 2022, JCI insight.

[2]  I. Schmidtmann,et al.  Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample , 2022, Viruses.

[3]  M. Abdulnabi,et al.  Hematological changes associated with COVID‐19 infection , 2021, Journal of clinical laboratory analysis.

[4]  G. Tarantino,et al.  PaO2/FiO2 ratio forecasts COVID-19 patients’ outcome regardless of age: a cross-sectional, monocentric study , 2021, Internal and Emergency Medicine.

[5]  John D Lambris,et al.  Phase 2a clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. , 2021, The Journal of clinical investigation.

[6]  M. Vargas,et al.  Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series , 2021, Seminars in Thrombosis and Hemostasis.

[7]  D. Annane,et al.  Complement Inhibition and COVID-19: The Story so Far , 2021, ImmunoTargets and therapy.

[8]  P. Boor,et al.  Complement activation induces excessive T cell cytotoxicity in severe COVID-19 , 2021, Cell.

[9]  Isaac B. Woodhouse,et al.  Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19 , 2021, Cell Reports Medicine.

[10]  G. Bowlin,et al.  Patients with COVID-19: in the dark-NETs of neutrophils , 2021, Cell Death & Differentiation.

[11]  Shuangge Ma,et al.  Diverse functional autoantibodies in patients with COVID-19 , 2021, Nature.

[12]  C. D. Dela Cruz,et al.  Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection , 2021, Science Immunology.

[13]  Dave L Dixon,et al.  Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 , 2021, Nature Reviews Immunology.

[14]  Tristan Frum,et al.  SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation , 2021, Science Immunology.

[15]  A. Mangoni,et al.  The PaO2/FiO2 ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients. , 2021, Journal of infection in developing countries.

[16]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[17]  G. Barbara,et al.  Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis , 2021, Endoscopy.

[18]  J. Atkinson,et al.  Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. , 2021, bioRxiv.

[19]  B. Nilsson,et al.  The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System , 2021, Frontiers in Immunology.

[20]  R. McBane,et al.  Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients , 2021, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

[21]  Yandong Liu,et al.  A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019 , 2021, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[22]  B. Souweine,et al.  Association Between Early Invasive Mechanical Ventilation and Day-60 Mortality in Acute Hypoxemic Respiratory Failure Related to Coronavirus Disease-2019 Pneumonia , 2021, Critical care explorations.

[23]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[24]  R. Halbgebauer,et al.  Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. , 2020, Blood.

[25]  B. Clary,et al.  Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis , 2020, EClinicalMedicine.

[26]  S. Zakynthinos,et al.  ICU-acquired bloodstream infections in critically ill patients with COVID-19☆ , 2020, Journal of Hospital Infection.

[27]  D. Annane,et al.  Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study , 2020, EClinicalMedicine.

[28]  N. Petrosillo,et al.  Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect” , 2020, Journal of Global Antimicrobial Resistance.

[29]  M. Jaeger,et al.  Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes , 2020, The Journal of infectious diseases.

[30]  C. Cogliati,et al.  Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study , 2020, BMJ Open.

[31]  P. van Paassen,et al.  Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial , 2020, The Lancet Rheumatology.

[32]  Karl Erik Müller,et al.  Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients , 2020, Proceedings of the National Academy of Sciences.

[33]  John D Lambris,et al.  Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy , 2020, Clinical Immunology.

[34]  Jessica K De Freitas,et al.  Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection , 2020, Nature Medicine.

[35]  F. Vély,et al.  Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis , 2020, Nature.

[36]  R. Busse,et al.  Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study , 2020, The Lancet Respiratory Medicine.

[37]  J. Atkinson,et al.  The complement system in COVID-19: friend and foe? , 2020, JCI insight.

[38]  John D Lambris,et al.  Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.

[39]  P. Pelosi,et al.  Bloodstream infections in critically ill patients with COVID‐19 , 2020, European journal of clinical investigation.

[40]  F. Blasi,et al.  Complement activation in patients with COVID-19: A novel therapeutic target , 2020, Journal of Allergy and Clinical Immunology.

[41]  John D Lambris,et al.  Complement as a target in COVID-19? , 2020, Nature Reviews Immunology.

[42]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[43]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[44]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[45]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[46]  B. Nilsson,et al.  Safety profile after prolonged C3 inhibition. , 2018, Clinical immunology.

[47]  S. Lorkowski,et al.  Kallikrein Cleaves C3 and Activates Complement , 2017, Journal of Innate Immunity.

[48]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[49]  B. Nilsson,et al.  Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[50]  E. Conway,et al.  Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin , 2016, EBioMedicine.

[51]  John D. Lambris,et al.  Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention , 2015, European journal of clinical investigation.

[52]  Hongjun Bai,et al.  New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. , 2013, Immunobiology.

[53]  John D Lambris,et al.  Molecular Intercommunication between the Complement and Coagulation Systems , 2010, The Journal of Immunology.

[54]  John D Lambris,et al.  Generation of C5a in the absence of C3: a new complement activation pathway , 2006, Nature Medicine.

[55]  Dimitrios Morikis,et al.  Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin1 , 2000, The Journal of Immunology.

[56]  D. Dickson.  The story so far… , 2000, Nature.

[57]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[58]  藤倉雄二,et al.  わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .

[59]  Dimitrios Morikis,et al.  Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. , 2003, Molecular immunology.